It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Introduction
In recent axSpAx patients with remission lasting at least 3 months and later followed-up monthly for a median of 8 months, we compared the predictive value of baseline MRI of sacroiliac joints and constructed a nomogram model for predicting flare.
Methods
This study included 251 patients with axial spondyloarthritis, according to the ASAS axSpA classification criteria, who achieved Low Disease Activity (ASDAS) and underwent MRI examination. A total of 144 patients from the First Affiliated Hospital of Xiamen University were used as the nomogram training set; 107 from the First Affiliated Hospital of Fujian Medical University were for external validation.
Results
The median time of relapse was 8.705 months (95% CI 8.215–9.195) and 7.781 months (95% CI 7.075–8.486) for MRI-positive patients and 9.8 months (95% CI 9.273–10.474) for MRI negative patients, respectively. Both active sacroiliitis on MRI (HR 1.792, 95% CI 1.230–2.611) and anti-TNF-α treatments (HR 0.507, 95% CI 0.349–0.736) were significantly associated with disease flares. Gender, disease duration, HLA-B27, MRI, and anti-TNF-α treatment were selected as predictors of the nomogram. The areas under the ROC curve (AUROCs) of the 1-year remission probability in the training and validation groups were 0.71 and 0.729, respectively. Nomogram prediction models present better AUROCs, C-indices, and decision curve analysis cure than the clinical experience model.
Conclusions
Active sacroiliitis in MRI requires weighting in order to estimate remission and disease flares, when axSpA patients achieve low disease activity. The simple nomogram might be able to discriminate and calibrate in clinical practice.
Trial registration
ClinicalTrials, NCT03425812, Registered 8 February 2018, https://clinicaltrials.gov
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 The First Affiliated Hospital of Xiamen University, Department of Rheumatology and Clinical Immunology, Xiamen, China (GRID:grid.412625.6); The First Affiliated Hospital of Fujian Medical University, Department of Rheumatology and Clinical Immunology, Fuzhou, China (GRID:grid.412683.a) (ISNI:0000 0004 1758 0400)
2 The First Affiliated Hospital of Xiamen University, Department of Rheumatology and Clinical Immunology, Xiamen, China (GRID:grid.412625.6)
3 Fujian Maternity and Child Health Hospital, Department of Anesthesiology, Fuzhou, China (GRID:grid.412625.6)
4 The First Affiliated Hospital of Xiamen University, Department of Rheumatology and Clinical Immunology, Xiamen, China (GRID:grid.412625.6); The Affiliated Hospital of Hubei Minzu University, Rheumatology Department, Enshi, China (GRID:grid.412625.6)
5 The First Affiliated Hospital of Xiamen University, Department of Rheumatology and Clinical Immunology, Xiamen, China (GRID:grid.412625.6); Xiamen University, School of Medicine, Xiamen City, China (GRID:grid.12955.3a) (ISNI:0000 0001 2264 7233)
6 The First Affiliated Hospital of Xiamen University, Department of Rheumatology and Clinical Immunology, Xiamen, China (GRID:grid.412625.6); The First Affiliated Hospital of Xiamen University, CT Department, Xiamen, China (GRID:grid.412625.6)
7 The First Affiliated Hospital of Fujian Medical University, Department of Ultrasound, Fuzhou, China (GRID:grid.412683.a) (ISNI:0000 0004 1758 0400)
8 The First Affiliated Hospital of Fujian Medical University, Department of Radiology, Fuzhou, China (GRID:grid.412683.a) (ISNI:0000 0004 1758 0400)
9 The First Affiliated Hospital of Fujian Medical University, Department of Rheumatology and Clinical Immunology, Fuzhou, China (GRID:grid.412683.a) (ISNI:0000 0004 1758 0400)
10 The First Affiliated Hospital of Xiamen University, Epidemiology Research Unit, Center of Translational Medical Research, Xiamen, China (GRID:grid.412625.6)